Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"Completed
NCT04033367Phase 4Updated Sep 17, 2025
Sponsor: Sanofi
Atopic Dermatitis
United States, Australia, France, Germany, Israel +5 more
Excretion Balance, Pharmacokinetics, and Metabolism Following of [14C]-Venglustat Administration in Healthy Male SubjectsCompleted
NCT05238714Phase 1Updated Sep 17, 2025
Sponsor: Genzyme, a Sanofi Company
Disorders of Sphingolipid Metabolism · Healthy Volunteers
United Kingdom
A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia ACompleted
NCT04161495Phase 3Updated Sep 17, 2025
Sponsor: Bioverativ, a Sanofi company
Factor VIII Deficiency
United States, Argentina, Australia, Belgium, Brazil +14 more
Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of AgeCompleted
NCT04210349Phase 3Updated Sep 16, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza
China
Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single and Repeated Doses of SAR444336 in Healthy Adult ParticipantsCompleted
NCT05876767Phase 1Updated Sep 16, 2025
Sponsor: Sanofi
Healthy Volunteer
Netherlands
Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related ToxicityTerminated
NCT05128773Phase 3Updated Sep 16, 2025
Sponsor: Sanofi
Breast Cancer
Chile, China
A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566Completed
NCT05844735Phase 1Updated Sep 16, 2025
Sponsor: Sanofi
Rheumatoid Arthritis
United States
Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic DermatitisCompleted
NCT04823130Phase 4Updated Sep 16, 2025
Sponsor: Sanofi
Dermatitis Atopic
United States, Germany
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid TumorsTerminated
NCT04242147Phase 1Updated Sep 16, 2025
Sponsor: Kadmon, a Sanofi Company
Solid Tumor
United States
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational StudyActive Not Recruiting
NCT05991323N/AUpdated Sep 16, 2025
Sponsor: Sanofi
Prurigo Nodularis
United States, Canada, China, France, Japan +1 more
Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult SubjectsCompleted
NCT05845996Phase 1Updated Sep 16, 2025
Sponsor: Sanofi
Healthy Volunteers
United States
Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of AgeCompleted
NCT04368429Phase 3Updated Sep 15, 2025
Sponsor: Sanofi
Meningococcal Immunisation (Healthy Volunteers)
Japan
Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)Completed
NCT04084769Phase 3Updated Sep 15, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation (Healthy Volunteers)
United States, Puerto Rico
Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type ⅢCompleted
NCT04656600Phase 4Updated Sep 15, 2025
Sponsor: Sanofi
Gaucher's Disease
China
Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European ToddlersCompleted
NCT03890367Phase 3Updated Sep 15, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation (Healthy Volunteers)
Denmark, Finland, Germany
Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic DermatitisCompleted
NCT04718870Phase 4Updated Sep 15, 2025
Sponsor: Sanofi
Dermatitis Atopic
United States, United Kingdom
Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and OlderCompleted
NCT05426174Phase 1Updated Sep 15, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza Immunization · Healthy Volunteers
United States
Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in JapanCompleted
NCT05132127Phase 3Updated Sep 15, 2025
Sponsor: Sanofi
Cold Agglutinin Disease
Japan
A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic FunctionCompleted
NCT05718258Phase 1Updated Sep 15, 2025
Sponsor: Sanofi
Hepatic Function Abnormal
United States, Germany
Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in ChinaCompleted
NCT05624112Phase 4Updated Sep 15, 2025
Sponsor: Sanofi
Atopic Dermatitis · Dermatitis Atopic
China
Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid TumorsTerminated
NCT05013554Phase 1Updated Sep 15, 2025
Sponsor: Sanofi
Neoplasm Malignant · Breast Cancer · Lung Neoplasm Malignant · Gastric Cancer
United States, Belgium, France, South Korea, Spain +1 more
Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy AdolescentsCompleted
NCT04490018Phase 3Updated Sep 12, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation · Healthy Volunteers
Hungary, Italy, Singapore, Spain
Bioavailability Study of Fexofenadine HCl New Formulation TabletCompleted
NCT06284902Phase 1Updated Sep 12, 2025
Sponsor: Opella Healthcare Group SAS, a Sanofi Company
Healthy Volunteers
Canada
Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)Completed
NCT04045795Phase 1Updated Sep 12, 2025
Sponsor: Sanofi
Multiple Myeloma
United States, Australia, Belgium, France, Japan +1 more
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, RespectivelyCompleted
NCT05050318Phase 4Updated Sep 12, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza Immunization · Healthy Volunteers
United States

Previous page Next page